When control over prescription drug access rests with only a few players, the result is not just market imbalance — it is higher plan costs, increased financial pressures, and ultimately reduced affordability for patients.
Any successful response to skyrocketing drug costs has to also actively manage medications at the individual level — just because someone can be on a medication doesn’t mean they should be.
In an interview, Munich Re Specialty Senior Vice President Jim Craig talked about the risk that accompanies innovation and the important role that insurers play.
Quantum Health launched its Premier Pharmacy navigation solution on Tuesday. The solution helps members find safe and effective therapeutic alternatives to expensive medications.
MedImpact and GoodRx are teaming up to lower costs for MedImpact members. When eligible MedImpact members refill a generic prescription, the companies' savings solution will compare the member's benefit to GoodRx's price and will automatically apply the lowest one.
CVS Caremark and GoodRx created a new program called Caremark Cost Saver, which will become available starting January 1, 2024. Through the program, eligible CVS Caremark commercially insured members will have access to GoodRx’s prescription pricing on generic medications.
Implementing a specialty pharmacy strategy and approach for growth not only creates a revenue stream for the system, but also establishes a high-touch patient engagement program that becomes a differentiator in the way service is delivered for their community.
CEO and neuroscientist Dr. Iftach Dolev on how the new device can bring a powerful tool to psychiatrists and neurologists alike.
The National Alliance of Healthcare Purchaser Coalitions released a playbook on Monday that outlines the key concerns employers have about pharmacy benefit management, and provides several recommendations for employers.
A bipartisan group of House representatives introduced the Drug Price Transparency in Medicaid Act on Friday. The bill would ban spread pricing in Medicaid programs.
During an interview at the AHIP Medicare, Medicaid, Duals and Commercial Markets Forum held Tuesday in Washington, D.C., CMS Administrator Chiquita Brooks-LaSure discussed CMS' key focus areas for 2023. This includes the end of the public health emergency, health equity and prescription drug costs.
The U.S. Department of Health & Human Services announced three models Tuesday that will be tested by the CMS Innovation Center and aim to lower prescription drug costs. The models, which include access to $2 generic drugs, build on the Inflation Reduction Act of 2022.
Greenway Health blends smart technology with human expertise to elevate revenue cycle.
President Biden continues to center his pre-midterm speeches around the issue of prescription drug costs, with two recent West Coast talks highlighting how Democrats will continue to work to lower costs for seniors. At a community center in Portland, Oregon on Saturday, three weeks ahead of the midterms, the President described an executive order he’d […]